Breakpoint Therapeutics GmbH

"Modulating DNA Damage Responses to Cure Cancer"

Where it wins

• Targets therapy-resistant cancers by interfering with DNA repair and replication stress pathways, addressing a high unmet medical need where current treatments fail [1].
• Leverages a highly virtual, capital-efficient model using Evotec's fully established, validated, and industrialised R&D platforms to accelerate discovery and pre-clinical development [1].
• Backed by a renowned consortium (Medicxi, Taiho Ventures, Evotec) providing early-stage financing and strategic industry expertise, reducing execution risk for early-stage assets [1].

Credibility: Evotec press release, 08 July 2019, detailing the spin-off structure, funding, and strategic rationale [1].

• Virtual biotech model: Operates with minimal physical infrastructure, leveraging Evotec's existing R&D platforms for capital efficiency and flexibility [1].
• Asset-centric approach: Focuses on advancing multiple complementary drug discovery programmes initiated at Evotec, aiming to deliver IND-ready drugs rapidly [1].
• Strategic spin-off: Created as a separate entity to isolate and accelerate the development of DDR-targeting assets, with Evotec retaining a significant stake [1].

• PARP inhibitor developers: Companies like AstraZeneca and Merck, which have successfully developed PARP inhibitors, face competition from Breakpoint's broader DDR-targeting approach [1].
• Other DDR-focused biotechs: Emerging companies targeting DDR pathways, though Breakpoint's virtual model and Evotec backing provide a unique advantage [1].
• Differentiators: Breakpoint's capital-efficient virtual model, access to Evotec's platforms, and strong investor consortium position it well for rapid advancement of DDR drugs [1].

• Therapy-resistant cancers: Many cancer patients do not respond to existing treatments, leading to high mortality rates [1].
• Side effects of current therapies: Existing treatments like radiation and chemotherapy often cause significant side effects, reducing quality of life [1].
• Limited treatment options: Lack of effective drugs for cancers with specific genetic alterations in DDR pathways [1].

Breakpoint Therapeutics' virtual model and strategic partnerships position it to efficiently advance DDR-targeting drugs, addressing a critical unmet need in oncology. The main risk is the high failure rate of early-stage drug development, which could impact investor returns. The opportunity lies in the growing interest in DDR therapies, following the success of PARP inhibitors. The next signal to watch is the delivery of the first IND-ready drug in 2022, which would validate the company's approach and attract further investment.

Breakpoint should actively seek out additional strategic partnerships with larger pharmaceutical companies to accelerate drug development and commercialization. Expanding the investor base beyond the current consortium could provide additional capital and industry connections. Enhancing patient engagement strategies could help build support for DDR-targeting therapies and provide valuable insights into patient needs.